You can buy or sell Translate Bio and other stocks, options, and ETFs commission-free!
Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Read More Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. The listed name for TBIO is Translate Bio, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 5, After Hours